ANXA11 and amyotrophic lateral sclerosis: In addition, ANXA11-ALS cases had a longer median survival (4.3 years [IQR 2.2–7.6] vs. 2.7 years [IQR 1.7–5.2]), though this difference was not statistically significant (p = 0.46).